-J R Bertino Researcher Activity Profile

Research Author Detailed Information 

J R Bertino Publication Rate By Year

J R Bertino has published 1 paper(s) in 1967, 1 paper(s) in 1968, 1 paper(s) in 1972, 1 paper(s) in 1973, 1 paper(s) in 1975, 4 paper(s) in 1976, 1 paper(s) in 2000, 8 paper(s) in 2007, for a total of 18 research publications in total.

J R Jr Bertino Author Information

LAST NAME: bertino

FIRST NAME: J R

INITIALS: jr

AFFILIATION:

Papers

J R Bertino's Publication Record

1. Expression of bone morphogenetic proteins and receptors in sarcomas. Year Published: 2000
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
2. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Year Published: 2007
Department of Pharmacology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903, USA.
3. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Year Published: 2007
Hematology Service.
4. Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity. Year Published: 2007
Department of Medicine and Pharmacology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903, USA.
5. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Year Published: 2007
Hematology Service, New York, NY, USA. moskowic@mskcc.org
6. Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity. Year Published: 2007
Department of Medicine and Pharmacology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903, USA.
7. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Year Published: 2007
Hematology Service, New York, NY, USA. moskowic@mskcc.org
8. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Year Published: 2007
Hematology Service, New York, NY, USA. moskowic@mskcc.org
9. Recent developments in chemotherapy of malignancy. Year Published: 1975
10. Chemotherapeutic approaches to advanced carcinoma of the larynx. Year Published: 1976
11. Pharmacogenomics of microRNA: a miRSNP towards individualized therapy. Year Published: 2007
12. Methotrexate (NSC-740) in squamous cell carcinoma of the head and neck. II. Intermittent intravenous therapy. Year Published: 1967
13. Head and neck cancer. 3. Toxicity of 24-hour infusions of methotrexate (NSC-740) and protection by leucovorin (NSC-3590) in patients with epidermoid carcinomas. Year Published: 1968
14. Short-term sequential therapy with vinblastine (NSC-49842) and cyclophosphamide (NSC-26271) in Hodgkin's disease. Year Published: 1972
15. Treatment of advanced neoplastic disease with 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037). Year Published: 1973
16. Preclinical studies with triazinate (NSC-139105), an antifolate drug, in beagle dogs and rhesus monkeys. Year Published: 1976
17. Absorption of leucovorin (NSC-3590) from a "mouthwash". Year Published: 1976
18. Combination chemotherapy with cyclophosphamide (NSC-26271), cytosine arabinoside (NSC-63878), and methotrexate (NSC-740) in advanced solid tumors. Year Published: 1976